Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-0a52b09545f0b2e00d5c72212ca2a403"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-0a52b09545f0b2e00d5c72212ca2a403"/>
<resource>
<Composition>
<id value="composition-en-0a52b09545f0b2e00d5c72212ca2a403"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-0a52b09545f0b2e00d5c72212ca2a403"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-0a52b09545f0b2e00d5c72212ca2a403</b></p><a name="composition-en-0a52b09545f0b2e00d5c72212ca2a403"> </a><a name="hccomposition-en-0a52b09545f0b2e00d5c72212ca2a403"> </a><a name="composition-en-0a52b09545f0b2e00d5c72212ca2a403-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1085/004</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - taltz</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1085/004"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp0a52b09545f0b2e00d5c72212ca2a403"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - taltz"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Taltz is and what it is used for</li><li>What you need to know before you use Taltz</li><li>How to use Taltz</li><li>Possible side effects</li><li>How to store Taltz</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What taltz is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What taltz is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Taltz contains the active substance ixekizumab.</p><p>Taltz is intended for the treatment of the inflammatory diseases described below:</p><ul><li>Plaque psoriasis in adults</li><li>Plaque psoriasis in children from the age of 6 and with a body weight of at least 25 kg and in adolescents</li><li>Psoriatic arthritis in adults</li><li>Radiographic Axial Spondyloarthritis in adults</li><li>Non-radiographic Axial Spondyloarthritis in adults</li></ul><p>Ixekizumab belongs to a group of medicines called interleukin (IL) inhibitors. This medicine works by blocking the activity of a protein called IL-17A, which promotes psoriasis and inflammatory disease of the joints and the spine.</p><p>Plaque psoriasis Taltz is used to treat a skin condition called plaque psoriasis in adults and in children from the age of 6 years and with a body weight of at least 25 kg and in adolescents with moderate to severe disease. Taltz reduces the signs and symptoms of the disease.</p><p>Using Taltz will benefit you by improvements of skin clearance and reducing your symptoms such as scaling, itching and pain.</p><p>Psoriatic arthritis<br/>Taltz is used to treat a condition called psoriatic arthritis in adults, an inflammatory disease of the joints, often accompanied by psoriasis. If you have psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines or in case of intolerance, you will be given Taltz to reduce the signs and symptoms of the disease. Taltz can be used alone or with another medicine named methotrexate.</p><p>Using Taltz will benefit you by reducing the signs and symptoms of the disease, improving physical function (ability to do normal daily activities), and slowing down the damage to the joints. Axial spondyloarthritis Taltz is used to treat adults with an inflammatory disease primarily affecting the spine which causes inflammation of the spinal joints, called axial spondyloarthritis. If the condition is visible using X-rays, it is referred to as radiographic axial spondyloarthritis ; if it occurs in patients with no visible signs on X-rays, it is referred to as non-radiographic axial spondyloarthritis . If you have axial spondyloarthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Taltz to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take taltz"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take taltz"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Taltz</p><ul><li>if you are allergic to ixekizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Taltz.</li><li>if you have an infection which your doctor thinks is important (for example, active tuberculosis).</li></ul><p>Warnings and precautions Talk to your doctor before using Taltz:</p><ul><li>if you currently have an infection or if you have long-term or repeated infections.</li><li>if you have an inflammatory disease affecting the gut named Crohn s disease.</li><li>if you have an inflammation of the large intestine named ulcerative colitis.</li><li>if you are receiving any other treatment for psoriasis (such as immunosuppressant or phototherapy with ultraviolet light) or for psoriatic arthritis.</li></ul><p>Inflammatory bowel disease (Crohn's disease or ulcerative colitis) Stop using Taltz and tell your doctor or seek medical help immediately if you notice abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (any signs of bowel problems).</p><p>If you are not sure if any of the above applies to you, talk to your doctor or nurse before using Taltz.</p><p>Look out for infections and allergic reactions Taltz can potentially cause serious side effects, including infections and allergic reactions. You must look out for signs of these conditions while you are using Taltz.</p><p>Stop using Taltz and tell your doctor or seek medical help immediately if you notice any signs of a serious infection or an allergic reaction. Such signs are listed under Serious side effects in section 4. Children and adolescents Do not use this medicine for the treatment of plaque psoriasis in children under 6 years of age because it has not been studied in this age group.</p><p>Do not use this medicine for the treatment of psoriatic arthritis in children and adolescents under 18 years of age because it has not been studied in this age group.</p><p>Other medicines and Taltz Tell your doctor, pharmacist or nurse</p><ul><li>if you are using, have recently used or might use any other medicines.</li><li>if you have recently had or are due to have a vaccination. You should not be given certain types of vaccines while using Taltz.</li></ul><p>Pregnancy and breast-feeding If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine.<br/>It is preferable to avoid the use of Taltz in pregnancy. The effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Taltz and for at least 10 weeks after the last Taltz dose.</p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. You and your doctor should decide if you can breast-feed or use Taltz. You should not do both.</p><p>Driving and using machines Taltz is unlikely to influence your ability to drive and use machines.</p><p>Taltz contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take taltz"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take taltz"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>Taltz is given by injection under your skin (subcutaneous injection). You and your doctor or nurse should decide if you should inject Taltz yourself.</p><p>For use in children with a body weight of 25-50 kg ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional.</p><p>It is important not to try to inject yourself until you have been trained by your doctor or nurse. A caregiver may also give you your Taltz injection after proper training.</p><p>Use a reminder method such as notes in a calendar or diary to help you remember your next dose so that you avoid missing or repeating doses.</p><p>Taltz is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.</p><p>Each syringe contains one dose of Taltz (80 mg). Each syringe delivers only one dose. The syringe must not be shaken.</p><p>Read the Instructions for use for the syringe carefully before using Taltz.</p><p>How much Taltz is given and for how long Your doctor will explain to you how much Taltz you need and for how long.</p><p>Plaque psoriasis in adults</p><ul><li>The first dose is 160 mg (2 syringes with 80 mg each) by subcutaneous injection. This may be given by your doctor or nurse.</li><li>After the first dose, you will use an 80 mg dose (1 syringe) at weeks 2, 4, 6, 8, 10, and 12. From week 12, you will use an 80 mg dose (1 syringe) every 4 weeks.</li></ul><p>Plaque psoriasis in children (age 6 years and above and at least 25 kg body weight) and in adolescents. The recommended dose given by subcutaneous injection in children is based on the following weight categories:</p><p>Children s body weight Recommended starting dose (week 0) Recommended dose every 4 weeks (Q4W) thereafter Greater than 50 kg<br/>160 mg (2 syringes) 80 mg (1 syringe) 25 to 50 kg 80 mg (1 syringe) 40 mg (dose preparation required)</p><p>40 mg preparation of ixekizumab in children Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional. Taltz is not recommended for use in children with a body weight below 25 kg.</p><p>Psoriatic arthritis<br/>For psoriatic arthritis patients who also have moderate to severe plaque psoriasis:</p><ul><li>The first dose is 160 mg (2 syringes with 80 mg each) by subcutaneous injection. This may be given by your doctor or nurse.</li><li>After the first dose, you will use an 80 mg dose (1 syringe) at weeks 2, 4, 6, 8, 10, and 12. From week 12, you will use an 80 mg dose (1 syringe) every 4 weeks.</li></ul><p>For other psoriatic arthritis patients</p><ul><li>The first dose is 160 mg (2 syringes with 80 mg each) by subcutaneous injection. This may be given by your doctor or nurse.</li><li>After the first dose you will use an 80 mg dose (1 syringe) every 4 weeks.</li></ul><p>Axial spondyloarthritis<br/>The recommended dose is 160 mg (2 syringes with 80 mg each) by subcutaneous injection at week 0, followed by 80 mg (1 syringe) every 4 weeks.</p><p>If you use more Taltz than you should If you have received more Taltz than you should or the dose has been given sooner than prescribed, inform your doctor.</p><p>If you forget to use Taltz If you have forgotten to inject a dose of Taltz, talk to your doctor.</p><p>If you stop using Taltz<br/>You should not stop using Taltz without speaking to your doctor first. If you stop treatment, symptoms of psoriasis or psoriatic arthritis may come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects<br/>Stop using Taltz and tell your doctor or seek medical help immediately if you get any of the following side effects. Your doctor will decide if and when you may restart the treatment:</p><p>Possible serious infection (may affect up to 1 in 100 people) - the signs may include:</p><ul><li>fever, flu-like symptoms, night sweats</li><li>feeling tired or short of breath, cough which will not go away</li><li>warm, red and painful skin, or a painful skin rash with blisters</li></ul><p>Serious allergic reaction (may affect up to 1 in 1,000 people) - the signs may include:</p><ul><li>difficulty breathing or swallowing</li><li>low blood pressure, which can cause dizziness or light-headedness</li><li>swelling of the face, lips, tongue or throat</li><li>severe itching of the skin, with a red rash or raised bumps</li></ul><p>Other side effects that have been reported:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>upper respiratory tract infections with symptoms such as sore throat and stuffy nose.</li><li>injection site reactions (e.g. red skin, pain).</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>nausea.</li><li>fungal infections such as athlete s foot.</li><li>pain in the back of the throat.</li><li>cold sores of mouth, skin and mucous membranes (herpes simplex, mucocutaneous)</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>oral thrush (oral candidiasis).</li><li>influenza.</li><li>runny nose.</li><li>bacterial skin infection.</li><li>hives.</li><li>discharge from the eye with itching, redness and swelling (conjunctivitis).</li><li>signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia).</li><li>low blood platelet count (thrombocytopenia).</li><li>eczema</li><li>rash</li><li>rapid swelling of the tissues of the neck, face, mouth or throat (angioedema)</li><li>abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems).</li></ul><p>Rare (may affect up to 1 in 1 000 people)</p><ul><li>fungal infection of the oesophagus (oesophageal candidiasis)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store taltz"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store taltz"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the syringe label and on the outer carton after EXP . The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C to 8 C). Do not freeze. Do not push to the back panel of the fridge.</p><p>Store in the original packaging in order to protect from light.</p><p>Taltz can be left out of the fridge for up to 5 days at a temperature not above 30 C.</p><p>Do not use this medicine if you notice that the syringe is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.</p><p>This medicine is for single use only.</p><p>Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Taltz contains</p><ul><li>The active substance is ixekizumab.</li></ul><p>Each pre-filled syringe contains 80 mg of ixekizumab in 1 ml solution.</p><ul><li>The other ingredients are sucrose; polysorbate 80; water for injections. In addition, sodium hydroxide may have been added for pH adjustment.</li></ul><p>What Taltz looks like and contents of the pack Taltz is a solution in a clear glass syringe. Its colour may vary from colourless to slightly yellow.</p><p>Pack sizes of 1, 2, 3 pre-filled syringes. Not all pack sizes may be available in your country.</p><p>Marketing Authorisation Holder<br/>Eli Lilly and Company (Ireland) Limited, Dunderrow, Kinsale, Co. Cork, Ireland.</p><p>Manufacturer Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino (FI), Italy.</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgique/Belgi /Belgien Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649<br/>" " . . -<br/>. + 359 2 491 41 Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 esk republika ELI LILLY R, s.r.o. Tel: + 420 234 664 Magyarorsz g Lilly Hung ria Kft. Tel: + 36 1 328 5Danmark Eli Lilly Danmark A/S<br/>Tlf: +45 45 26 60 Malta Charles de Giorgio Ltd. Tel: + 356 25600 Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2Nederland Eli Lilly Nederland B.V.<br/>Tel: + 31-(0) 30 60 25 Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 Norge Eli Lilly Norge A.S.<br/>Tlf: + 47 22 88 18</p><ul><li>. . . .<br/>: +30 210 629 4 sterreich Eli Lilly Ges.m.b.H.<br/>Tel: + 43-(0) 1 711 Espa a Lilly S.A. Tel: + 34-91 663 50 Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 France Lilly France T l: +33-(0) 1 55 49 34 Portugal Lilly Portugal Produtos Farmac uticos, Lda Tel: + 351-21-4126Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 Rom nia Eli Lilly Rom nia S.R.L. Tel: + 40 21 4023Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4Slovenija Eli Lilly farmacevtska dru ba, d.o.o. Tel: +386 (0)1 580 00 sland Icepharma hf. S mi + 354 540 8Slovensk republika Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42Suomi/Finland Oy Eli Lilly Finland Ab<br/>Puh/Tel: + 358-(0) 9 85 45<br/>Phadisco Ltd<br/>: +357 22 715Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378Latvija Eli Lilly (Suisse) S.A P rst vniec ba Latvij<br/>Tel: +371 67364United Kingdom (Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4This leaflet was last revised in</li></ul><p>Other sources of information</p><h2 id="detailed-information-on-this-medicine-is-available-on-the-european-medicines-agency-website-httpwwwemaeuropaeu">Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</h2><p>The following information is intended for medical or healthcare professionals only:</p><p>40 mg preparation of ixekizumab for children 25-50 kg body weight</p><p>Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional. Use only the Taltz 80 mg solution for injection in pre-filled syringe when preparing the prescribed 40 mg paediatric doses.</p><ol type="1"><li>Expel the entire contents of the pre-filled syringe into a sterile, clear glass vial. DO NOT shake or swirl the vial.</li><li>Use a 0.5 ml or 1 ml disposable syringe and sterile needle to withdraw the prescribed dose (0.5 ml for 40 mg) from the vial.</li><li>Change the needle and use a 27-gauge, sterile needle to inject the patient. Discard any unused ixekizumab in the vial.</li></ol><p>The prepared ixekizumab must be administered within 4 hours of puncturing the sterile vial at room temperature.</p><p>Instructions for use</p><p>Taltz 80 mg solution for injection in pre-filled syringe</p><p>ixekizumab</p><p>Before using your pre-filled syringe:</p><p>Important points to know</p><ul><li>Before you use the Taltz pre-filled syringe, read and carefully follow all the step-by-step instructions. Keep the Instructions for use and refer to them as needed.</li><li>The pre-filled syringe contains 1 dose of Taltz. The syringe is for ONE-TIME USE ONLY.</li><li>The syringe must not be shaken.</li><li>Your doctor, pharmacist or nurse may help you decide where on your body to inject your dose.</li><li>Read the Taltz Package Leaflet inside this box to learn more about your medicine.</li></ul><p>INSTRUCTIONS FOR USE</p><p>Before you use the Taltz pre-filled syringe, read and carefully follow all the step-by-step instructions.</p><p>Guide to the parts</p><p>1 GET READY</p><p>1a Take the syringe from the refrigerator. Leave the needle cap on the syringe until you are ready to inject. Wait 30 minutes to let the syringe warm to room temperature before you use it.</p><p>DO NOT use any heat sources to warm the medicine, for example: a microwave, hot water, or direct sunlight.</p><p>1b Gather the supplies for your injection:</p><ul><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps container for disposal of syringes</li></ul><p>Finger grips minutes Thumb pad Green plunger rod Syringe body with medicine Needle Needle cap Grey syringe plunger 1c</p><p>Inspect the pre-filled syringe for damage to the outside. Leave the needle cap on the syringe until you are ready to inject. Check the label. Make sure the name Taltz appears on the label.</p><p>The medicine inside should be clear. Its colour may vary from colourless to slightly yellow.</p><p>If you see any of the following, DO NOT USE the syringe, and dispose of it as directed:</p><ul><li>It is past the expiry date.</li><li>It looks damaged.</li><li>The medicine is cloudy, is distinctly brown, or has small particles.</li></ul><p>1d Wash your hands before you inject your medicine.</p><p>1e</p><p>Choose your injection site.</p><p>You may inject in your abdomen (stomach area), in your thigh, or in the back of your arm. To inject in your arm, you will need someone to help you.</p><p>DO NOT inject into areas where the skin is tender, bruised, red, or hard or where you have scars or stretch marks. DO NOT inject within 2.5 centimetres of the navel (belly button).</p><p>Alternate your injection sites. DO NOT inject in the exact same spot every time. For example, if your last injection was in your left thigh, your next injection should be in your right thigh, your abdomen, or the back of either arm.</p><p>1f Prepare your skin. Clean your skin with an alcohol wipe. Let the injection site dry naturally before you inject your medicine.</p><p>Back of arm Abdomen Thigh Expiry date 2 INJECT</p><p>2a</p><p>Pull the needle cap off and throw it away.</p><p>DO NOT put the needle cap back on you could damage the needle or injure yourself by accident.</p><p>DO NOT touch the needle.</p><p>2b</p><p>Gently pinch and hold a fold of skin where you will inject.</p><p>2c</p><p>Insert the needle at a 45-degree angle. Then gently let go of your skin. Make sure to keep the needle in place.</p><p>2d</p><p>Push in the plunger.</p><p>Slowly push the plunger all the way in until all the medicine is injected. The grey syringe plunger should be pushed all the way to the end of the syringe. Gently remove the needle from your skin.</p><p>Press a cotton ball or gauze over the injection site. DO NOT rub the injection site, as this may cause bruising. You may have slight bleeding. This is normal.</p><p>You should see the green plunger rod showing through the syringe body when the injection is complete.</p><p>3 FINISH</p><p>3a</p><p>Dispose of the pre-filled syringe.</p><p>DO NOT put the needle cap back on. Dispose of the syringe in a sharps container or as directed by your doctor, pharmacist or nurse.</p><p>When you dispose of syringes and the sharps container:</p><ul><li>Dispose of the syringe in a sharps container or as directed by your doctor, pharmacist or nurse.</li><li>Do not recycle the filled sharps container.</li><li>Ask your doctor, pharmacist or nurse about how to dispose of medicines you no longer use.</li></ul><p>Green plunger rod Grey syringe plunger Grey syringe plunger Green plunger rod Safety tips</p><ul><li>If you have questions or need help with your pre-filled syringe, call your doctor, pharmacist or nurse.</li><li>If you have vision problems, DO NOT use the pre-filled syringe without help from a person trained to use it.</li><li>DO NOT share or reuse your Taltz pre-filled syringe. You may give or get an infection</li><li>Keep the syringe out of the reach and sight of children.</li><li>If you do not have a sharps container, ask your doctor, pharmacist or nurse about where you can get one.</li></ul><p>Commonly asked questions</p><p>Q. What if I see air bubbles in my syringe?</p><p>A. It is normal to sometimes have air bubbles in the syringe. Taltz is injected under your skin (subcutaneous injection). Air bubbles are not a problem in this type of injection. They will not harm you or affect your dose.</p><p>Q. What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</p><p>A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.</p><p>Q. What if I cannot push in the plunger?</p><p>A. If the plunger is stuck or damaged:</p><ul><li><p>DO NOT continue to use the syringe.</p></li><li><p>Remove the needle from your skin.</p></li></ul><p>Q. How can I tell if my injection is complete?</p><p>A. When your injection is complete:</p><ul><li><p>The green plunger rod should show through the body of the syringe.</p></li><li><p>The grey syringe plunger should be pushed all the way to the end of the syringe.</p></li></ul><p>Q. What if the syringe is left at room temperature for longer than 30 minutes?</p><p>A. If needed, the syringe may be left out of the fridge at temperature not above 30 C for up to 5 days if protected from direct sunlight. Taltz should be discarded if not used within the 5 day period at room temperature.</p><p>Read the full Instructions for use and the package leaflet inside this box to learn more about your medicine.</p><p>Package leaflet: Information for the patient</p><p>Taltz 80 mg solution for injection in pre-filled pen ixekizumab</p><p>Read all of this leaflet carefully before you start using this medicine because it contains important information for you.</p><ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor, pharmacist or nurse.</li><li>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</li><li>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.</li></ul></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp0a52b09545f0b2e00d5c72212ca2a403"/>
<resource>
<MedicinalProductDefinition>
<id value="mp0a52b09545f0b2e00d5c72212ca2a403"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp0a52b09545f0b2e00d5c72212ca2a403"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp0a52b09545f0b2e00d5c72212ca2a403</b></p><a name="mp0a52b09545f0b2e00d5c72212ca2a403"> </a><a name="hcmp0a52b09545f0b2e00d5c72212ca2a403"> </a><a name="mp0a52b09545f0b2e00d5c72212ca2a403-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1085/004</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Taltz 80 mg solution for injection in pre-filled syringe</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1085/004"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Taltz 80 mg solution for injection in pre-filled syringe"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
